Cargando…
The Anti-Vascular Endothelial Growth Factor Receptor 1 (VEGFR-1) D16F7 Monoclonal Antibody Inhibits Melanoma Adhesion to Soluble VEGFR-1 and Tissue Invasion in Response to Placenta Growth Factor
SIMPLE SUMMARY: Melanoma is an aggressive cancer type with a high tendency to spread to distant body sites, including bones. Despite the availability of effective therapies, many patients still do not fully benefit from treatment. The aim of our study was to evaluate the therapeutic potential of inh...
Autores principales: | Atzori, Maria Grazia, Ceci, Claudia, Ruffini, Federica, Scimeca, Manuel, Cicconi, Rosella, Mattei, Maurizio, Lacal, Pedro Miguel, Graziani, Grazia |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9688925/ https://www.ncbi.nlm.nih.gov/pubmed/36428669 http://dx.doi.org/10.3390/cancers14225578 |
Ejemplares similares
-
Role of VEGFR‐1 in melanoma acquired resistance to the BRAF inhibitor vemurafenib
por: Atzori, Maria Grazia, et al.
Publicado: (2019) -
Role of VEGFs/VEGFR-1 Signaling and Its Inhibition in Modulating Tumor Invasion: Experimental Evidence in Different Metastatic Cancer Models
por: Ceci, Claudia, et al.
Publicado: (2020) -
Ellagic Acid Inhibits Bladder Cancer Invasiveness and In Vivo Tumor Growth
por: Ceci, Claudia, et al.
Publicado: (2016) -
Antitumor activity of a novel anti-vascular endothelial growth factor receptor-1 monoclonal antibody that does not interfere with ligand binding
por: Graziani, Grazia, et al.
Publicado: (2016) -
VEGF-A/VEGFR-1 signalling and chemotherapy-induced neuropathic pain: therapeutic potential of a novel anti-VEGFR-1 monoclonal antibody
por: Micheli, Laura, et al.
Publicado: (2021)